BioSpace News Archive

Dyne Therapeutics, Inc today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, provided a preliminary update on recent clinical activity and expected near term milestones for its lead program MB-106 for the treatment of Acute Myeloid Leukemia (AML) following its Fiscal Year 2023 filing with the Securities and Exchange Commission.

Rhythm Pharmaceuticals, Inc. today announced that the first patients have been dosed in the Company’s Phase 1 clinical trial of RM-718, an investigational, weekly melanocortin-4 receptor (MC4R)-specific agonist designed to be MC1R-sparing and to potentially avoid hyperpigmentation.

Ardelyx, Inc. today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to TNX-2900* (intranasal potentiated oxytocin), a proprietary magnesium (Mg2+)-potentiated formulation of intranasal oxytocin, to treat Prader-Willi syndrome (PWS) in children and adolescents.

Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.

Genetic Technologies Limited is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer test.

Olink Holding AB announced its unaudited financial results for the fourth quarter ended December 31, 2023.

Olink Holding AB announced that the Annual Report for 2023 is now available on the Company’s website.

Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has listed “No Action Indicated” or NAI status classification for the company’s Baltimore Bayview manufacturing facility.